Ocrevus Zunovo in Multiple Sclerosis: Real‑World Use and Patient Feedback

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This mixed-methods observational study will enroll 50 MS patients treated with Ocrevus Zunovo at Northwestern Memorial Hospital over 15–18 months to collect clinical data and patient-reported outcomes at enrollment, 6 months, and 12 months. The study will also conduct about 100 semi-structured interviews with patients, family members, and care and administrative staff to identify facilitators and barriers to using high-efficacy MS therapy in routine settings. Activities include validated questionnaires and qualitative interviews to synthesize practical strategies for improving access and persistence with Ocrevus Zunovo in real-world care. The research will not test a new drug but will examine implementation, feasibility, acceptability, and impact on disease outcomes in a real-world context. Eligible participants are adults with MS seen at Northwestern Medicine who are considering starting or restarting a DMT and who can commit to 12 months of follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age of 18 years or older
* Resident of the USA
* Seen at Northwestern Medicine
* Meets diagnostic criteria (2024) for MS, either RMS or PPMS
* Diagnosis of MS (G35) on file by a neurologist
* Wants to start or restart a DMT for MS
* Willing to be in a 12-month follow up study

Exclusion Criteria:

* Unclear diagnosis of MS
* Incarcerated
* Unable to provide informed consent
* Current participant in an MS or any experimental therapy clinical trial
* Moribund
* Unable to speak a language for which consent processes are available at Northwestern Hospitals
* Currently taking a DMT that has not been washed out (e.g. recent treatment with Cladribine, Natalizumab, sphingosine 1-phosphate inhibitor, implying the last DMT is still actively immunosuppressing the patient)
* Current chemotherapy
* History of stem cell transplant, CAR-T or other chemo-ablative procedures
* Unwilling to complete surveys over the course of the following 12 months
* No access to computer or telephone
* Prior allergic reaction or intolerance to Ocrelizumab IV or SubQ or any monoclonal antibody therapy
* Hypogammaglobulinemia IgG level \<500
* Leukopenia \<2.0
* Active hepatitis or latent hepatitis B
* Elevated liver enzymes 3 times the upper limit of normal
* Tuberculosis
* Current serious infection, e.g. COVID-19, shingles, active pneumonia, progressive multifocal leukoencephalopathy, etc.
* Currently pregnant, breastfeeding, or a person of childbearing capacity who is sexually active without a documented plan of current contraceptive methods.
* Any other diagnosis or reason deemed to make the participant unfit for participation by the study PI

Where it's running

• Northwestern Memorial Hospital
  Chicago, Illinois, United States Recruiting

Study contacts

• Study coordinator: Dylan Rice, B.A.
• Email: dylan.rice@northwestern.edu
• Phone: 312-503-5298

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treadmill-based virtual reality walking training for MS patients

  This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.

  Recruiting Shepherd Center, Atlanta GA · Atlanta, Georgia · NCT07927439

• Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS

  This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.

  Recruiting Cairo University · Giza, Giza Governorate · NCT07918339

• REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care

  This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.

  Recruiting Imperial College London · London and 2 other locations · NCT07899502

• Tolebrutinib in real-world MS care for patients treated by clinicians

  This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.

  Recruiting Sanofi · Marina, Abu Dhabi Emirate · NCT07898371

• Pilates via live video vs. prerecorded videos for people with multiple sclerosis

  This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.

  Recruiting Yuzuncu Yil University · Van · NCT07893925

• Cooling During Inpatient Rehab for People with MS

  This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.

  Recruiting Klinik Valens · Valens, Canton of St. Gallen · NCT07852156

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.